Cegedim Stock (CGM.PA): Health Tech Analysis

Cegedim stock (ALCGM, ISIN FR0000053506) is that of a French provider of software and services for healthcare professionals: pharmacists, doctors, health insurers and pharmaceutical manufacturers. Listed since 2025 on Euronext Growth Paris, the company is counting on artificial intelligence to revive growth after years of restoring its profitability.

This profile covers the Cegedim share price, the group’s business, its first-half 2026 results, the move to Euronext Growth, the dividend (suspended since 2022) and how to buy the shares — along with the risks that come with a small French technology stock.

Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Last updated: October 22, 2026

Cegedim Stock Price: Live Quote

The share price currently trades at €, a move of % over the session. Today the stock opened at € and has traded between € and €; the last close stands at €.

Over 52 weeks, the Cegedim share price has moved between € and €. Since the transfer to Euronext Growth, daily volumes have been lower, of the order of shares: limit orders are a must.

Cegedim SA: Key Financial Data

Sources: Yahoo Finance — price, market capitalization, P/E, annual accounts and dividend history, data as of October 23, 2026. Figures are indicative and quoted in the listing currency; this does not constitute investment advice.

Cegedim at a Glance: Technology Serving Healthcare

Founded in 1969, Cegedim was built around a simple idea: healthcare professionals spend a great deal of time on administrative tasks, and technology can spare them much of it. The group employs several thousand people, mostly in France.

Its business is organized around several pillars. First, the software for pharmacists: pharmacy management, third-party payment, dispensing — a French market where the group has historically been very present. Then, the services for health and life insurers: delegated management of policies and dematerialization of care claim forms. Finally, Business Services: outsourcing of administrative processes and document digitization.

What these businesses have in common: recurring revenue tied to multi-year contracts, in a sector — healthcare — whose administrative flows keep growing. It is this « annuity-like » profile that long justified interest in the stock, before the group went through years of restructuring.

The Business Segments in Detail

The first historical pillar, pharmacy software solutions, covers the whole life of a community pharmacy: inventory management, dispensing, third-party payment, invoicing to health insurance funds. In France, where the number of pharmacies is regulated and the installed base relatively stable, this business generates highly predictable subscription revenue — but growth limited to contract renewals and additional services.

The second pillar, health and life insurance services, involves managing part of insurers’ policies on their behalf: enrollment, reimbursements, tenders, customer relations. It is an industrialization business, where economies of scale make the difference. Insurers are increasingly outsourcing these processes, which supports the segment’s growth.

The third pillar, Business Services, brings together the outsourcing of administrative processes for large accounts: document digitization, flow management, on-demand services. It is the segment most exposed to the cycle of large contracts — and also the one that posted the strongest growth in the first half of 2026.

History: From Healthcare Administration to Digital

The company was born in 1969 in the orbit of the pharmaceutical industry, providing laboratories with information and marketing services aimed at healthcare professionals. From that origin it kept a unique asset: an intimate knowledge of the administrative circuits of French healthcare.

Over the decades, the group diversified through acquisitions — pharmacy software, management services for insurers, outsourcing — until it formed a complex ensemble of complementary businesses. The years from 2018 to 2022 were marked by restructurings, the disposal of non-strategic assets and the suspension of the dividend, while the accounts were cleaned up.

The move to Euronext Growth in 2025, followed by the profitability progress of 2026, belongs to the same trajectory: a smaller, more focused group seeking to turn its financial turnaround into a new phase of growth. For the shareholder, it is this transition — from turnaround to growth — that still has to be proven.

The Move to Euronext Growth: What Changes

In May 2025, Cegedim announced a plan to transfer its shares from Euronext Paris to Euronext Growth, the market for small and mid caps. Approved by the general meeting of June 13, 2025, the transfer was completed in mid-August 2025.

Management presented the decision as a way to restore visibility and appeal to the stock, which now ranks among the thirty largest market capitalizations on Euronext Growth, while benefiting from lighter regulatory requirements and lower listing costs.

For the shareholder, the change is concrete: the ticker becomes ALCGM, liquidity tightens, and the company escapes certain disclosure obligations that apply to large caps. Cegedim remains a French company, eligible for the PEA and the PEA-PME — France’s tax-advantaged share savings plans — the Growth segment being precisely designed for listed SMEs and mid-sized companies.

Why the Cegedim Share Price Moves

• Half-year results: the profitability trajectory — EBITDA, operating income — has been the stock’s main driver since the turnaround.
• Organic growth: the business advances slowly; every acceleration or slowdown in the various segments is closely watched.
• Announcements on AI: the strategy laid out around artificial intelligence feeds hopes of a higher valuation.
• Liquidity: on Euronext Growth, a few orders are enough to move the price.
• Public healthcare spending: consultation fees, statutory agreements and administrative regulation weigh on the budgets of the group’s clients.

To these factors add the stock’s history: after difficult years that led to the suspension of the dividend, the market is waiting for proof that the turnaround turns into durable growth. As long as that proof is missing, the share price remains sensitive to every release.

The French Digital Health Market

The administrative spending of French healthcare feeds a deep but tightly supervised market. The spread of universal third-party payment, the dematerialization of exchanges between professionals and health insurance funds, the interoperability required of medical software: every reform creates obligations — and therefore work for the vendors that help professionals comply.

The flip side of this vein: prices for healthcare solutions are largely administered, and the budgets of healthcare professionals depend on negotiations with the health insurance system. A vendor like Cegedim lives in this balance — between structural tailwinds and regulatory pressure on prices. It is also one of the few health tech stocks France lists that gives investors direct exposure to this market.

Against this backdrop, two readings coexist. The first sees a mature market, growing slowly but highly defensible. The second sees an untapped reservoir of automation that AI could transform in depth over the coming decade. The stock’s trajectory will depend on the group’s ability to settle that question through concrete action.

H1 2026 Results: Profitability Improves

On September 24, 2026, Cegedim published higher half-year results despite a demanding sector environment:

Source: half-year release of September 24, 2026. The sharp rise in operating income is partly explained by the reduction in non-recurring charges — a base effect more than a surge in activity.

Some units are pulling the group forward: Business Services and health and life insurance post the strongest growth — the clearest Cegedim growth drivers at this stage. Artificial intelligence remains at the heart of the announced strategy, both to improve internal tools and to enrich client offerings — for instance to automate the processing of healthcare documents.

How to Read a Cegedim Earnings Release

Three figures deserve your attention. Organic growth, which separates real activity from perimeter effects. The adjusted EBITDA, the measure of the recurring profitability of the services model. And net income and net debt, which condition any return of the dividend.

Reported operating income can jump from one half-year to the next without reflecting a change in the business: non-recurring charges, restructurings and one-off items blur its reading. Hence the value of tracking the adjusted figure rather than the reported one.

Ouvrir un compte Vantage →

AI at Cegedim: Where It Really Serves

The group’s communications put artificial intelligence at the heart of its strategy, and the claim is worth unpacking. Internally, AI first serves to cut the cost of services: document recognition, automatic data extraction, processing of care claim forms. On a model that relies on a large workforce, every point of productivity gained directly improves the margin.

On the product side, AI enriches the software that is sold: dispensing support for the pharmacist, automation of policy management for the insurer. The question for the investor is monetization: will these features justify price premiums, or will they become an expected standard at no extra cost?

The healthcare administration sector combines the assets AI thrives on — document volumes, codified rules, costly errors — but also a constraint: medical data is sensitive, governed by the GDPR and the rules of the health insurance system. The vendors that master this balance between automation and compliance hold a genuine competitive advantage.

Cegedim Stock: Strengths and Risks

Cegedim Stock: Key Figures

The gauge places the current price within the 52-week range:

The last five trading sessions of ():

Cegedim Dividend: Suspended Since 2022

Cegedim no longer pays a dividend. The last one dates back to June 29, 2022, at €0.50 per share; no distribution has taken place since, the group devoting its resources to deleveraging and its transformation.

The return of a dividend would be a strong signal of financial normalization — but none has been announced. Until then, the stock offers only potential capital gains, and suits patient investors better than those seeking immediate income. For the latter, our selection of the best dividend stocks presents paying alternatives.

Competition and Positioning Among French Software Stocks

Cegedim operates in niche markets where competition takes different forms. In pharmacy software, specialized vendors compete for a stabilized French installed base. In management services for health insurers, the group faces both generalist IT services firms and healthcare specialists. In services, the pressure comes from the big outsourcing players.

Against the technology giants, Cegedim cannot compete on size: the group plays the sector-specialization card — French healthcare administration — where knowledge of the flows and regulations forms a barrier to entry. Our profile for buying IBM stock illustrates the opposite: a global generalist putting AI at the service of every sector. Among listed French software vendors, Wallix stock shows another path: specialization on a cybersecurity niche.

The investor’s bet is therefore twofold: that profitability keeps improving, and that healthcare specialization protects the group from the commoditization of management software.

Is Cegedim a Good Investment in 2026?

The bull case: steadily improving profitability, recurring revenue from multi-year contracts, a credible AI strategy in an administratively heavy sector, and a small-cap valuation largely spared from excesses.

The risks: weak organic growth, a dividend still suspended, reduced liquidity since the move to Euronext Growth, and dependence on the regulatory evolution of French healthcare.

To follow the story, two dates matter each year: the half-year results in September, which show the margin trajectory, and the full-year results in spring, which clarify the distribution policy. In between, quarterly revenue figures take the pulse of organic growth.

The typical profile: a patient investor with an interest in French technology mid caps, willing to wait for confirmation of growth before any capital gain. A prudent approach consists in limiting the weight of the position and following the half-year releases. Invested capital is not guaranteed.

How to Buy Cegedim Stock from France

1. Identify the stock: Cegedim SA, ticker ALCGM, ISIN FR0000053506, Euronext Growth Paris.
2. Choose the wrapper: a French company listed on a regulated European market, the stock is eligible for the PEA and the PEA-PME, with capital gains exempt from tax after five years.
3. Check access to Euronext Growth with your broker: some institutions charge more for these orders than for those on the main market.
4. Place a limit order: reduced liquidity makes market orders risky; our guide to stock market orders details the options.
5. Follow the calendar: quarterly revenue, half-year results in September and full-year results in spring.

For broader exposure to mid-sized French technology stocks, a fund or an ETF dedicated to listed European SMEs can complement a direct position in Cegedim — at the price of a more diluted exposure.

Cegedim Stock: Frequently Asked Questions

Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

The Key Takeaways

• Listing: Euronext Growth Paris (ALCGM), ISIN FR0000053506 — PEA and PEA-PME eligible.
• Business: software and services for healthcare — pharmacists, doctors, insurers.
• Results: H1 2026 — revenue €324.8m, adjusted EBITDA €62.0m, operating income +82.9%.
• Dividend: suspended since June 2022.
• Growth drivers: AI, improving profitability, recurring healthcare revenues.
• Risks: weak organic growth, reduced liquidity on Growth.